Occam Places Chief Development Officer of Groundbreaking Longevity Player, Loyal
In May 2024, Occam recruited Hubert Chen, MD as Chief Development Officer of Loyal, a biotech company pioneering longevity drugs for dogs. Since its founding in 2019, Loyal has raised $125M from blue chip VCs including Bain and Khosla. The company currently has three drugs in development to extend healthy lifespan in dogs and anticipates the most advanced drug will be available in early 2025, pending FDA conditional approval.
Chen brings two decades of translational and clinical development experience within human therapeutics to Loyal’s animal health pipeline. Hubert came to Loyal from Forte Biosciences, where he served as Chief Medical Officer. He was formerly the Chief Medical Officer of metabolic biotech Metacrine and the Chief Scientific and Medical Officer of protein technology platform biotech Pfenex, leading up to its sale to Ligand Pharmaceuticals. Hubert has an MD from Columbia University and a BA from Stanford University.
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.